Monte Historical Cash Flow
| GLUE Stock | USD 5.66 0.10 1.74% |
Analysis of Monte Rosa cash flow over time is an excellent tool to project Monte Rosa Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Change In Cash of 68.5 M or Net Borrowings of 7.2 M as it is a great indicator of Monte Rosa ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Monte Rosa Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Monte Rosa Therapeutics is a good buy for the upcoming year.
Monte |
About Monte Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Monte balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Monte's non-liquid assets can be easily converted into cash.
Monte Rosa Cash Flow Chart
Add Fundamental
Net Borrowings
The difference between the amount of new debt a company has taken on and the amount of debt it has paid off during a given period.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Depreciation
Depreciation indicates how much of Monte Rosa Therapeutics value has been used up. For tax purposes Monte Rosa can deduct the cost of the tangible assets it purchases as business expenses. However, Monte Rosa Therapeutics must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.Capital Expenditures
Capital Expenditures are funds used by Monte Rosa Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Monte Rosa operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Monte Rosa Therapeutics financial statement analysis. It represents the amount of money remaining after all of Monte Rosa Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Most accounts from Monte Rosa's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Monte Rosa Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Monte Rosa Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. At present, Monte Rosa's Change In Cash is projected to increase significantly based on the last few years of reporting. The current year's Stock Based Compensation is expected to grow to about 20.1 M, whereas Free Cash Flow is forecasted to decline to (59.4 M).
Monte Rosa cash flow statement Correlations
Click cells to compare fundamentals
Monte Rosa Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Monte Rosa cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Investments | (3.4M) | (9.7M) | (206.4M) | 20.6M | 18.5M | 19.4M | |
| Change In Cash | 33.6M | 308.5M | (291.2M) | 72.5M | 65.2M | 68.5M | |
| Stock Based Compensation | 354K | 5.2M | 11.7M | 16.7M | 19.2M | 20.1M | |
| Free Cash Flow | (26.4M) | (69.1M) | (105.4M) | (62.8M) | (56.6M) | (59.4M) | |
| Change In Working Capital | 4.3M | 6.3M | (2.1M) | 72.5M | 83.3M | 87.5M | |
| Begin Period Cash Flow | 9.2M | 42.9M | 351.4M | 60.2M | 69.2M | 102.4M | |
| Other Cashflows From Financing Activities | 60.5M | 139.8M | 411K | 27.5M | 24.7M | 36.6M | |
| Depreciation | 537K | 2.1M | 3.7M | 6.2M | 7.2M | 7.5M | |
| Other Non Cash Items | 7.7M | 960K | 2.8M | (3.8M) | (3.4M) | (3.3M) | |
| Capital Expenditures | 3.4M | 9.7M | 12.9M | 19.0M | 21.9M | 23.0M | |
| Total Cash From Operating Activities | (23.1M) | (59.4M) | (92.5M) | (43.8M) | (39.4M) | (41.4M) | |
| Net Income | (35.9M) | (74.0M) | (108.5M) | (135.4M) | (121.8M) | (115.7M) | |
| Total Cash From Financing Activities | 60.1M | 377.6M | 20.5M | 27.5M | 24.7M | 23.5M | |
| End Period Cash Flow | 42.9M | 351.4M | 60.2M | 132.7M | 152.6M | 131.2M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Monte Rosa Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Monte Rosa. If investors know Monte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Monte Rosa listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Monte Rosa Therapeutics is measured differently than its book value, which is the value of Monte that is recorded on the company's balance sheet. Investors also form their own opinion of Monte Rosa's value that differs from its market value or its book value, called intrinsic value, which is Monte Rosa's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Monte Rosa's market value can be influenced by many factors that don't directly affect Monte Rosa's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Monte Rosa's value and its price as these two are different measures arrived at by different means. Investors typically determine if Monte Rosa is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Monte Rosa's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.